- Home
- Companies
- Boehringer Ingelheim Animal Health USA ...
- Products
- VETMEDIN - Model CA1 - Chewable Tablets
VETMEDIN - Model CA1 -Chewable Tablets
VETMEDIN-CA1 (pimobendan) Chewable Tablets are indicated for the delay of onset of congestive heart failure in dogs with Stage B2 preclinical myxomatous mitral valve disease (2019 American College of Veterinary Internal Medicine Consensus Statement). It is a violation of Federal law to use VETMEDIN-CA1 other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-556. Adverse reactions not related to disease progression in dogs receiving VETMEDIN-CA1 included diarrhea, vomiting, pain, lameness, arthritis, urinary tract infection, and seizure.
The unique mode of action of VETMEDIN-CA1 (pimobendan) Chewable Tablets acts as both a positive inotrope and potent, balanced vasodilator, simultaneously dilating veins and arteries. In this form, the chew enters the GI tract and is rapidly dissolved and absorbed.
- Proprietary formulation ensures optimal bioavailability that in turn ensures optimal therapeutic effect
- Recommended by the American College of Veterinary Internal Medicine (Specialty of Cardiology) panel as part of first-line therapy in dogs diagnosed with Stage B2 myxomatous mitral valve disease (MMVD) to ensure optimal patient outcomes
- Beef-flavored chewable tablet ensures high levels of acceptability that in turn promotes compliance
- Meets FDA standards of product safety, stability, and strength